DSM Agrees To Buy Martek For $1.09 Billion

Photo by Bradley Stemke/flickr
Photo by Bradley Stemke/flickr

Dutch chemicals group DSM said on Tuesday it would buy Martek Biosciences Corporation for €829 million in cash to specialize further in the niche food nutrition industry.

DSM has been repositioning itself in recent years away from bulk chemicals to focus on niche life sciences and materials sciences and last week completed its divestment program, saying it had a war chest of €2 billion for acquisitions.

DSM said its offer price of $31.50 per Martek share represents a 35% premium to the U.S.-based company's closing share price on Dec. 20 and that Martek's board of directors is recommending the offer to shareholders.

The world's largest vitamins maker said the deal gives DSM a new growth platform for natural, healthy polyunsaturated fatty acids nutrition ingredients, adding that Martek is a global leader, especially in infant formula nutrition.

"This acquisition is an attractive and logical next step for DSM. Martek's leading position in healthy, natural ingredients and algal technology will add a new growth platform to our Nutrition business," said Chief Executive Feike Sijbesma, a medical biologist and business management graduate.

Martek had annual net sales of $450 million for its fiscal year which ended Oct. 31 and estimated earnings before interest, tax, depreciation and amortization (EBITDA) of $115 million to $120 million.

Based on the agreed acquisition price of $1.09 billion, DSM is paying about nine times estimated EBITDA.

Analysts have previously said DSM could become a takeover target if it does not make a large acquisition soon and the deal, DSM's first major buy after its divestment scheme, will be funded by DSM's existing cash.

The tender process is expected to start between Jan. 10 and Jan. 25 and close in February, while the deal is expected to close in the first or second quarter of 2011.

It is subject to the tendering of at least a majority of Martek shares and antitrust approval in the U.S. and other regulatory approvals.

DSM said the acquisition is immediately earnings per share accretive for DSM by 15 to 20 cents on a full-year basis. The acquisition is expected to realize material revenue synergies.

Company

Royal DSM N.V.


6401 JH Heerlen

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.